Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769766 · ClinicalTrials.gov registry record · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
A Phase 3 study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
- 1
- Study location
NCT03769766: Recruiting Phase 3 study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT03769766 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 291 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03769766, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Primary Outcome
The primary endpoint is the number of patients who have progressed at 2 years of follow up defined as one of the following events: receipt of primary therapy for prostate cancer (eg, prostatectomy, radiation, hormonal therapy) or pathologic progression (\> 4 cores involved, ≥ 50% of any core involved, or any Gleason score ≥ 7)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Curcumin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2030-11 |
| Phase | Phase 3 |
What NCT03769766 shows while recruiting
NCT03769766 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03769766 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03769766 about?
NCT03769766 is a clinical study titled "Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance". This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
What is the current status of trial NCT03769766?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2019-03-11. Estimated completion is 2030-11.
What conditions does trial NCT03769766 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03769766?
The interventions under investigation include: Placebo (DRUG), Curcumin (DRUG).
Who is sponsoring clinical trial NCT03769766?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03769766 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03769766's enrollment target sits among peer trials
291 168th of 735 higher than 568 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI